{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T02:53:54Z","timestamp":1777949634904,"version":"3.51.4"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Suzhou Municipal Health Commission Suzhou Science and Technology Research Program","award":["SYWD2025211"],"award-info":[{"award-number":["SYWD2025211"]}]},{"DOI":"10.13039\/501100015377","name":"Shanghai Key Laboratory of Molecular Imaging","doi-asserted-by":"publisher","award":["KFKT202435"],"award-info":[{"award-number":["KFKT202435"]}],"id":[{"id":"10.13039\/501100015377","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014869","name":"Chongqing Xinqiao Hospital, Second Affiliated Hospital of Army Medical University","doi-asserted-by":"publisher","award":["SDFEYJC2334"],"award-info":[{"award-number":["SDFEYJC2334"]}],"id":[{"id":"10.13039\/501100014869","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016086","name":"Key Laboratory in Science and Technology Development Project of Suzhou","doi-asserted-by":"publisher","award":["SKYD2023114"],"award-info":[{"award-number":["SKYD2023114"]}],"id":[{"id":"10.13039\/100016086","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-08045-w","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T10:06:11Z","timestamp":1774433171000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Head-to-head comparison between 18F-FDG and 18F-PSMA-1007 PET\/CT in diagnosing recurrent and metastatic prostate cancer"],"prefix":"10.1186","volume":"24","author":[{"given":"Ning","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaxi","family":"You","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiwei","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yirong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhihui","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yizhen","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6125-0626","authenticated-orcid":false,"given":"Zhijun","family":"Pei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"issue":"1","key":"8045_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"8045_CR2","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1007\/s00259-019-04620-0","volume":"47","author":"P Donato","year":"2020","unstructured":"Donato P, Morton A, Yaxley J, Ranasinghe S, Teloken PE, Kyle S, et al. (68)Ga-PSMA PET\/CT better characterises localised prostate cancer after MRI and transperineal prostate biopsy: Is (68)Ga-PSMA PET\/CT guided biopsy the future? Eur J Nucl Med Mol Imaging. 2020;47(8):1843\u201351.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Suppl 2","key":"8045_CR3","doi-asserted-by":"publisher","first-page":"S67","DOI":"10.2967\/jnumed.116.186767","volume":"58","author":"M Eiber","year":"2017","unstructured":"Eiber M, Fendler WP, Rowe SP, Calais J, Hofman MS, Maurer T, et al. Prostate-specific membrane antigen ligands for imaging and therapy. J Nucl Med. 2017;58(Suppl 2):S67\u201376.","journal-title":"J Nucl Med"},{"issue":"2","key":"8045_CR4","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","volume":"79","author":"N Mottet","year":"2021","unstructured":"Mottet N, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2021;79(2):243\u201362.","journal-title":"Eur Urol"},{"issue":"6","key":"8045_CR5","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1007\/s00259-017-3670-z","volume":"44","author":"WP Fendler","year":"2017","unstructured":"Fendler WP, Eiber M, Beheshti M, Bomanji J, Ceci F, Cho S, et al. (68)Ga-PSMA PET\/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2017;44(6):1014\u201324.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8045_CR6","doi-asserted-by":"crossref","unstructured":"Treglia G, Annunziata S, Pizzuto DA, Giovanella L, Prior JO, Ceriani L. Detection rate of (18)F-labeled PSMA PET\/CT in biochemical recurrent prostate cancer: a systematic review and a meta-analysis. Cancers (Basel). 2019;11(5).","DOI":"10.3390\/cancers11050710"},{"issue":"8","key":"8045_CR7","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1007\/s00259-018-3989-0","volume":"45","author":"K Rahbar","year":"2018","unstructured":"Rahbar K, Afshar-Oromieh A, Bogemann M, Wagner S, Schafers M, Stegger L, et al. (18)F-PSMA-1007 PET\/CT at 60 and 120 minutes in patients with prostate cancer: biodistribution, tumour detection and activity kinetics. Eur J Nucl Med Mol Imaging. 2018;45(8):1329\u201334.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"8045_CR8","doi-asserted-by":"publisher","first-page":"425","DOI":"10.2967\/jnumed.116.181768","volume":"58","author":"J Cardinale","year":"2017","unstructured":"Cardinale J, Schafer M, Benesova M, Bauder-Wust U, Leotta K, Eder M, et al. Preclinical evaluation of (18)F-PSMA-1007, a new prostate-specific membrane antigen ligand for prostate cancer imaging. J Nucl Med. 2017;58(3):425\u201331.","journal-title":"J Nucl Med"},{"issue":"1","key":"8045_CR9","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2967\/jnumed.125.269818","volume":"67","author":"K Rahbar","year":"2026","unstructured":"Rahbar K, Giesel FL, Herrmann K, Yun M, Watabe T, Rudolph I, et al. Efficacy of [(18)F]PSMA-1007 PET\/CT in primary staging of prostate carcinoma: a systematic review and meta analysis. J Nucl Med. 2026;67(1):85\u201391.","journal-title":"J Nucl Med"},{"issue":"3","key":"8045_CR10","doi-asserted-by":"publisher","first-page":"362","DOI":"10.2967\/jnumed.118.212233","volume":"60","author":"FL Giesel","year":"2019","unstructured":"Giesel FL, Knorr K, Spohn F, Will L, Maurer T, Flechsig P, et al. Detection efficacy of (18)F-PSMA-1007 PET\/CT in 251 patients with biochemical recurrence of prostate cancer after radical prostatectomy. J Nucl Med. 2019;60(3):362\u20138.","journal-title":"J Nucl Med"},{"issue":"4","key":"8045_CR11","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/s41391-023-00755-2","volume":"27","author":"S Huang","year":"2024","unstructured":"Huang S, Ong S, McKenzie D, Mirabelli A, Chen DC, Chengodu T, et al. Comparison of (18)F-based PSMA radiotracers with [(68)Ga]Ga-PSMA-11 in PET\/CT imaging of prostate cancer-a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2024;27(4):654\u201364.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"0 1","key":"8045_CR12","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1007\/s00259-013-2361-7","volume":"40","author":"H Jadvar","year":"2013","unstructured":"Jadvar H. Imaging evaluation of prostate cancer with 18F-fluorodeoxyglucose PET\/CT: utility and limitations. Eur J Nucl Med Mol Imaging. 2013;40(0 1):S5\u201310.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"8045_CR13","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1097\/RLU.0000000000006106","volume":"51","author":"Y Li","year":"2026","unstructured":"Li Y, Gao X, Yang J, Tang Y, Hu S. PSMA-negative widespread metastases identified by 18 F-FDG PET\/CT in treatment-related neuroendocrine prostate cancer with squamous differentiation. Clin Nucl Med. 2026;51(1):70\u20132.","journal-title":"Clin Nucl Med"},{"issue":"4","key":"8045_CR14","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1007\/s00259-025-07646-9","volume":"53","author":"R Chen","year":"2026","unstructured":"Chen R, Wang Y, Chen Q, Dong L, Huang G, Liu J. Dual-tracer PET\/CT identifies an aggressive PSMA-negative\/FDG-positive phenotype predicting early failure of radical prostatectomy in treatment-naive prostate cancer. Eur J Nucl Med Mol Imaging. 2026;53(4):2295\u2013303.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"8045_CR15","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1007\/s00259-020-04967-9","volume":"48","author":"N Ayati","year":"2021","unstructured":"Ayati N, Sadeghi R, Kiamanesh Z, Lee ST, Zakavi SR, Scott AM. The value of (18)F-FDG PET\/CT for predicting or monitoring immunotherapy response in patients with metastatic melanoma: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2021;48(2):428\u201348.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"8045_CR16","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.1097\/RLU.0000000000002367","volume":"44","author":"PM Perez","year":"2019","unstructured":"Perez PM, Hope TA, Behr SC, van Zante A, Small EJ, Flavell RR. Intertumoral heterogeneity of 18F-FDG and 68Ga-PSMA uptake in prostate cancer pulmonary metastases. Clin Nucl Med. 2019;44(1):e28\u201332.","journal-title":"Clin Nucl Med"},{"issue":"4","key":"8045_CR17","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1097\/RLU.0000000000002013","volume":"43","author":"GK Parida","year":"2018","unstructured":"Parida GK, Tripathy S, Datta Gupta S, Singhal A, Kumar R, Bal C, et al. Adenocarcinoma prostate with neuroendocrine differentiation: potential utility of 18F-FDG PET\/CT and 68Ga-DOTANOC PET\/CT Over 68Ga-PSMA PET\/CT. Clin Nucl Med. 2018;43(4):248\u20139.","journal-title":"Clin Nucl Med"},{"issue":"5","key":"8045_CR18","doi-asserted-by":"publisher","first-page":"731","DOI":"10.2967\/jnumed.122.264741","volume":"64","author":"R Seifert","year":"2023","unstructured":"Seifert R, Telli T, Hadaschik B, Fendler WP, Kuo PH, Herrmann K. Is (18)F-FDG PET Needed to Assess (177)Lu-PSMA Therapy Eligibility? A VISION-like, Single-Center Analysis. J Nucl Med. 2023;64(5):731\u20137.","journal-title":"J Nucl Med"},{"issue":"5","key":"8045_CR19","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.eururo.2023.02.002","volume":"83","author":"R Seifert","year":"2023","unstructured":"Seifert R, Emmett L, Rowe SP, Herrmann K, Hadaschik B, Calais J, et al. Second version of the prostate cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE V2). Eur Urol. 2023;83(5):405\u201312.","journal-title":"Eur Urol"},{"issue":"3","key":"8045_CR20","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2967\/jnumed.117.198119","volume":"59","author":"M Eiber","year":"2018","unstructured":"Eiber M, Herrmann K, Calais J, Hadaschik B, Giesel FL, Hartenbach M, et al. Prostate cancer molecular imaging standardized evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-Ligand PET\/CT. J Nucl Med. 2018;59(3):469\u201378.","journal-title":"J Nucl Med"},{"issue":"2","key":"8045_CR21","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1148\/radiol.2016142043","volume":"280","author":"JH O","year":"2016","unstructured":"O JH, Lodge MA, Wahl RL, Practical PERCIST. A simplified guide to PET response criteria in solid tumors 1.0. Radiology. 2016;280(2):576\u201384.","journal-title":"Radiology"},{"issue":"6","key":"8045_CR22","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/jamaoncol.2019.0096","volume":"5","author":"WP Fendler","year":"2019","unstructured":"Fendler WP, Calais J, Eiber M, Flavell RR, Mishoe A, Feng FY, et al. Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial. JAMA Oncol. 2019;5(6):856\u201363.","journal-title":"JAMA Oncol"},{"issue":"12","key":"8045_CR23","doi-asserted-by":"publisher","first-page":"4202","DOI":"10.1007\/s00261-020-02745-7","volume":"45","author":"Q Zou","year":"2020","unstructured":"Zou Q, Jiao J, Zou MH, Li MZ, Yang T, Xu L, et al. Semi-automatic evaluation of baseline whole-body tumor burden as an imaging biomarker of (68)Ga-PSMA-11 PET\/CT in newly diagnosed prostate cancer. Abdom Radiol (NY). 2020;45(12):4202\u201313.","journal-title":"Abdom Radiol (NY)"},{"issue":"12","key":"8045_CR24","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.2967\/jnumed.120.242057","volume":"61","author":"R Seifert","year":"2020","unstructured":"Seifert R, Herrmann K, Kleesiek J, Schafers M, Shah V, Xu Z, et al. Semiautomatically quantified tumor volume using (68)Ga-PSMA-11 PET as a biomarker for survival in patients with advanced prostate cancer. J Nucl Med. 2020;61(12):1786\u201392.","journal-title":"J Nucl Med"},{"issue":"2","key":"8045_CR25","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1097\/JU.0000000000001369","volume":"205","author":"F Crocerossa","year":"2021","unstructured":"Crocerossa F, Marchioni M, Novara G, Carbonara U, Ferro M, Russo GI, et al. Detection rate of prostate specific membrane antigen tracers for positron emission tomography\/computerized tomography in prostate cancer biochemical recurrence: a systematic review and network meta-analysis. J Urol. 2021;205(2):356\u201369.","journal-title":"J Urol"},{"issue":"1","key":"8045_CR26","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s40644-023-00599-y","volume":"23","author":"W Yu","year":"2023","unstructured":"Yu W, Zhao M, Deng Y, Liu S, Du G, Yan B, et al. Meta-analysis of (18) F-PSMA-1007 PET\/CT, (18) F-FDG PET\/CT, and (68)Ga-PSMA PET\/CT in diagnostic efficacy of prostate Cancer. Cancer Imaging. 2023;23(1):77.","journal-title":"Cancer Imaging"},{"key":"8045_CR27","doi-asserted-by":"publisher","first-page":"1607227","DOI":"10.3389\/fmed.2025.1607227","volume":"12","author":"CM Iacovitti","year":"2025","unstructured":"Iacovitti CM, Cuzzocrea M, Rizzo A, Bauckneht M, Delgado Bolton RC, Paone G, et al. Diagnostic value of dual-tracer PET\/CT with [(18)F]FDG and PSMA ligands in prostate cancer: an updated systematic review. Front Med (Lausanne). 2025;12:1607227.","journal-title":"Front Med (Lausanne)"},{"issue":"12","key":"8045_CR28","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1007\/s00259-017-3780-7","volume":"44","author":"S Sheikhbahaei","year":"2017","unstructured":"Sheikhbahaei S, Afshar-Oromieh A, Eiber M, Solnes LB, Javadi MS, Ross AE, et al. Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging. Eur J Nucl Med Mol Imaging. 2017;44(12):2117\u201336.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"8045_CR29","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","volume":"86","author":"P Cornford","year":"2024","unstructured":"Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer-2024 update. Part I: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2024;86(2):148\u201363.","journal-title":"Eur Urol"},{"key":"8045_CR30","doi-asserted-by":"crossref","unstructured":"Cheung R, et al. In regards to: Roach defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix consensus conference. Int J Radiat Oncol Biol Phys. 2006;66(4):1274; author reply 1274\u20135.","DOI":"10.1016\/j.ijrobp.2006.07.010"},{"issue":"8","key":"8045_CR31","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1007\/s00259-024-06674-1","volume":"51","author":"Y Wang","year":"2024","unstructured":"Wang Y, Dong L, Zhao H, Li L, Huang G, Xue W, et al. The superior detection rate of total-body [(68)Ga]Ga-PSMA-11 PET\/CT compared to short axial field-of-view [(68)Ga]Ga-PSMA-11 PET\/CT for early recurrent prostate cancer patients with PSA\u2009<\u20090.2 ng\/mL after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2024;51(8):2484\u201394.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"8045_CR32","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00259-020-04934-4","volume":"48","author":"S Fanti","year":"2021","unstructured":"Fanti S, Goffin K, Hadaschik BA, Herrmann K, Maurer T, MacLennan S, et al. Consensus statements on PSMA PET\/CT response assessment criteria in prostate cancer. Eur J Nucl Med Mol Imaging. 2021;48(2):469\u201376.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"8045_CR33","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1007\/s00259-020-05040-1","volume":"48","author":"R Seifert","year":"2021","unstructured":"Seifert R, Kessel K, Schlack K, Weber M, Herrmann K, Spanke M, et al. PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [(177)Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis. Eur J Nucl Med Mol Imaging. 2021;48(4):1200\u201310.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"8045_CR34","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.eururo.2019.06.030","volume":"76","author":"A Paschalis","year":"2019","unstructured":"Paschalis A, Sheehan B, Riisnaes R, Rodrigues DN, Gurel B, Bertan C, et al. Prostate-specific membrane antigen heterogeneity and DNA repair defects in prostate cancer. Eur Urol. 2019;76(4):469\u201378.","journal-title":"Eur Urol"},{"issue":"6","key":"8045_CR35","doi-asserted-by":"publisher","first-page":"904","DOI":"10.2967\/jnumed.119.231068","volume":"61","author":"MK Bakht","year":"2020","unstructured":"Bakht MK, Lovnicki JM, Tubman J, Stringer KF, Chiaramonte J, Reynolds MR, et al. Differential expression of glucose transporters and hexokinases in prostate cancer with a neuroendocrine gene signature: a mechanistic perspective for 18F-FDG Imaging of PSMA-suppressed tumors. J Nucl Med. 2020;61(6):904\u201310.","journal-title":"J Nucl Med"},{"key":"8045_CR36","doi-asserted-by":"crossref","unstructured":"Jung T, Neureiter D, Schweighofer-Zwink G, Rendl G, Pirich C, Beheshti M. B-CLL with negative 18F-FDG PET\/CT and intensive solitary lesion on PSMA PET\/CT mimicking prostate cancer bone metastases. EJNMMI Rep. 2025;9(1).","DOI":"10.1186\/s41824-024-00235-3"},{"key":"8045_CR37","doi-asserted-by":"crossref","unstructured":"Doroudinia A, Wolfe T. FDG PET\/CT scan still can help in evaluation of prostate cancer. Clin Nucl Med. 2024.","DOI":"10.1097\/RLU.0000000000005518"},{"issue":"Suppl 1","key":"8045_CR38","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.2967\/jnumed.123.266968","volume":"65","author":"W Yang","year":"2024","unstructured":"Yang W, Kang F, Chen Y, Zhu Z, Wang F, Qin C, et al. Landscape of nuclear medicine in China and its progress on theranostics. J Nucl Med. 2024;65(Suppl 1):S29\u201337.","journal-title":"J Nucl Med"},{"key":"8045_CR39","doi-asserted-by":"crossref","unstructured":"Xu L, Chen R, Yu X, Liu J, Wang Y. (18)F-FDG PET is not inferior to (68)Ga-PSMA PET for detecting biochemical recurrent prostate cancer with a high gleason score: a head-to-head comparison study. Diagnostics (Basel). 2023;14(1).","DOI":"10.3390\/diagnostics14010007"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08045-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08045-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08045-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T02:29:38Z","timestamp":1777861778000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08045-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8045"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08045-w","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]},"assertion":[{"value":"21 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was conducted in accordance with the Declaration of Helsinki. It was approved by the ethics committee of The Second Affiliated Hospital of Soochow University (JD-LK2024027-IR01), and each patient signed an informed consent form.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"623"}}